Jennifer Adair to Genetic Therapy
This is a "connection" page, showing publications Jennifer Adair has written about Genetic Therapy.
Connection Strength
4.915
-
Harlow EM, Adair JE. Make gene therapies more available by manufacturing them in lower-income nations. Nature. 2024 Jul; 631(8021):502-504.
Score: 0.572
-
Adair JE, Anthony-Gonda K, Bayigga L, Orentas R, Mutuluuza CK, Mathews V, Dropulic B. Place-of-care manufacturing of gene therapies. Lancet Haematol. 2022 11; 9(11):e807-e808.
Score: 0.510
-
Flotte TR, Adair JE. Black Lives Matter to Gene Therapy. Hum Gene Ther. 2020 07; 31(13-14):700.
Score: 0.434
-
Adair JE, Chandrasekaran D, Sghia-Hughes G, Haworth KG, Woolfrey AE, Burroughs LM, Choi GY, Becker PS, Kiem HP. Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A. Haematologica. 2018 11; 103(11):1806-1814.
Score: 0.378
-
Adair JE, Kubek SP, Kiem HP. Hematopoietic Stem Cell Approaches to Cancer. Hematol Oncol Clin North Am. 2017 10; 31(5):897-912.
Score: 0.359
-
Adair JE, Sevilla J, Heredia CD, Becker PS, Kiem HP, Bueren J. Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. Curr Gene Ther. 2017; 16(5):338-348.
Score: 0.340
-
Adair JE, Waters T, Haworth KG, Kubek SP, Trobridge GD, Hocum JD, Heimfeld S, Kiem HP. Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. Nat Commun. 2016 10 20; 7:13173.
Score: 0.336
-
Adair JE, Johnston SK, Mrugala MM, Beard BC, Guyman LA, Baldock AL, Bridge CA, Hawkins-Daarud A, Gori JL, Born DE, Gonzalez-Cuyar LF, Silbergeld DL, Rockne RC, Storer BE, Rockhill JK, Swanson KR, Kiem HP. Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest. 2014 Sep; 124(9):4082-92.
Score: 0.288
-
Adair JE, Weitzman MD. Applying the speed-dating model and other approaches to foster future leaders for the American Society of Gene and Cell Therapy. Mol Ther. 2014 Aug; 22(8):1397-1398.
Score: 0.288
-
Adair JE, Beard BC, Trobridge GD, Neff T, Rockhill JK, Silbergeld DL, Mrugala MM, Kiem HP. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med. 2012 May 09; 4(133):133ra57.
Score: 0.247
-
Doxzen KW, Adair JE, Fonseca Bazzo YM, Bukini D, Cornetta K, Dalal V, Guerino-Cunha RL, Hongeng S, Jotwani G, Kityo-Mutuluuza C, Lakshmanan K, Mahlangu J, Makani J, Mathews V, Ozelo MC, Rangarajan S, Scholefield J, Batista Silva J?nior J, McCune JM. The translational gap for gene therapies in low- and middle-income countries. Sci Transl Med. 2024 May 08; 16(746):eadn1902.
Score: 0.142
-
Adair JE, Rubinger KS, Flotte TR. Women Lead Gene Therapy Science in 2021. Hum Gene Ther. 2021 04; 32(7-8):317-318.
Score: 0.114
-
Haworth KG, Ironside C, Ramirez MA, Weitz S, Beard BC, Schwartz JD, Adair JE, Kiem HP. Minimal conditioning in Fanconi anemia promotes multi-lineage marrow engraftment at 10-fold lower cell doses. J Gene Med. 2018 10; 20(10-11):e3050.
Score: 0.096
-
Humbert O, Chan F, Rajawat YS, Torgerson TR, Burtner CR, Hubbard NW, Humphrys D, Norgaard ZK, O'Donnell P, Adair JE, Trobridge GD, Scharenberg AM, Felsburg PJ, Rawlings DJ, Kiem HP. Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy. Blood Adv. 2018 05 08; 2(9):987-999.
Score: 0.093
-
Karponi G, Psatha N, Lederer CW, Adair JE, Zervou F, Zogas N, Kleanthous M, Tsatalas C, Anagnostopoulos A, Sadelain M, Rivi?re I, Stamatoyannopoulos G, Yannaki E. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood. 2015 Jul 30; 126(5):616-9.
Score: 0.076
-
Burtner CR, Chandrasekaran D, Santos EB, Beard BC, Adair JE, Hamlin DK, Wilbur DS, Sandmaier BM, Kiem HP. (211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy. Hum Gene Ther. 2015 Jun; 26(6):399-406.
Score: 0.076
-
O'Reilly M, Federoff HJ, Fong Y, Kohn DB, Patterson AP, Ahmed N, Asokan A, Boye SE, Crystal RG, De Oliveira S, Gargiulo L, Harper SQ, Ikeda Y, Jambou R, Montgomery M, Prograis L, Rosenthal E, Sterman DH, Vandenberghe LH, Zoloth L, Abedi M, Adair J, Adusumilli PS, Goins WF, Gray J, Monahan P, Popplewell L, Sena-Esteves M, Tannous B, Weber T, Wierda W, Gopal-Srivastava R, McDonald CL, Rosenblum D, Corrigan-Curay J. Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013. Hum Gene Ther. 2014 Jun; 25(6):488-97.
Score: 0.071
-
Burtner CR, Beard BC, Kennedy DR, Wohlfahrt ME, Adair JE, Trobridge GD, Scharenberg AM, Torgerson TR, Rawlings DJ, Felsburg PJ, Kiem HP. Intravenous injection of a foamy virus vector to correct canine SCID-X1. Blood. 2014 Jun 05; 123(23):3578-84.
Score: 0.070
-
Beard BC, Adair JE, Trobridge GD, Kiem HP. High-throughput genomic mapping of vector integration sites in gene therapy studies. Methods Mol Biol. 2014; 1185:321-44.
Score: 0.069
-
Adair JE, Zhao X, Chien S, Fang M, Wohlfahrt ME, Trobridge GD, Taylor JA, Beard BC, Kiem HP, Becker PS. Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities. J Mol Med (Berl). 2012 Nov; 90(11):1283-94.
Score: 0.062
-
Watts KL, Adair J, Kiem HP. Hematopoietic stem cell expansion and gene therapy. Cytotherapy. 2011 Nov; 13(10):1164-71.
Score: 0.059
-
Tolar J, Adair JE, Antoniou M, Bartholomae CC, Becker PS, Blazar BR, Bueren J, Carroll T, Cavazzana-Calvo M, Clapp DW, Dalgleish R, Galy A, Gaspar HB, Hanenberg H, Von Kalle C, Kiem HP, Lindeman D, Naldini L, Navarro S, Renella R, Rio P, Sevilla J, Schmidt M, Verhoeyen E, Wagner JE, Williams DA, Thrasher AJ. Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting. Mol Ther. 2011 Jul; 19(7):1193-8.
Score: 0.057
-
Becker PS, Taylor JA, Trobridge GD, Zhao X, Beard BC, Chien S, Adair J, Kohn DB, Wagner JE, Shimamura A, Kiem HP. Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector. Gene Ther. 2010 Oct; 17(10):1244-52.
Score: 0.054
-
Olayiwola O, Castillejo A, Louella M, Supercharger M, Harlow E, Dee L, Abdallah K, Kityo-Mutuluuza C, Adair JE, Orentas R, Dub? K. Nothing about us without us: Advocacy and engagement in genetic medicine. Sci Transl Med. 2024 May 08; 16(746):eadn2401.
Score: 0.035
-
Joo JH, Wang X, Singh S, Chen CY, Li C, Adair JE, Kiem HP, Rawlings DJ, Miao CH. Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice. Blood Adv. 2022 10 11; 6(19):5556-5569.
Score: 0.032
-
Peterson CW, Adair JE, Wohlfahrt ME, Deleage C, Radtke S, Rust B, Norman KK, Norgaard ZK, Schefter LE, Sghia-Hughes GM, Repetto A, Baldessari A, Murnane RD, Estes JD, Kiem HP. Autologous, Gene-Modified Hematopoietic Stem and Progenitor Cells Repopulate the Central Nervous System with Distinct Clonal Variants. Stem Cell Reports. 2019 07 09; 13(1):91-104.
Score: 0.025
-
Mrugala MM, Adair J, Kiem HP. Chemoprotection in glioblastoma therapy: reality or a dream? CNS Oncol. 2012 Sep; 1(1):11-4.
Score: 0.016
-
Beard BC, Trobridge GD, Ironside C, McCune JS, Adair JE, Kiem HP. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest. 2010 Jul; 120(7):2345-54.
Score: 0.014